Nakamura, K.; Asanuma, K.; Okamoto, T.; Iino, T.; Hagi, T.; Nakamura, T.; Sudo, A.
Combination of Everolimus and Bortezomib Inhibits the Growth and Metastasis of Bone and Soft Tissue Sarcomas via JNK/p38/ERK MAPK and AKT Pathways. Cancers 2023, 15, 2468.
https://doi.org/10.3390/cancers15092468
AMA Style
Nakamura K, Asanuma K, Okamoto T, Iino T, Hagi T, Nakamura T, Sudo A.
Combination of Everolimus and Bortezomib Inhibits the Growth and Metastasis of Bone and Soft Tissue Sarcomas via JNK/p38/ERK MAPK and AKT Pathways. Cancers. 2023; 15(9):2468.
https://doi.org/10.3390/cancers15092468
Chicago/Turabian Style
Nakamura, Koichi, Kunihiro Asanuma, Takayuki Okamoto, Takahiro Iino, Tomohito Hagi, Tomoki Nakamura, and Akihiro Sudo.
2023. "Combination of Everolimus and Bortezomib Inhibits the Growth and Metastasis of Bone and Soft Tissue Sarcomas via JNK/p38/ERK MAPK and AKT Pathways" Cancers 15, no. 9: 2468.
https://doi.org/10.3390/cancers15092468
APA Style
Nakamura, K., Asanuma, K., Okamoto, T., Iino, T., Hagi, T., Nakamura, T., & Sudo, A.
(2023). Combination of Everolimus and Bortezomib Inhibits the Growth and Metastasis of Bone and Soft Tissue Sarcomas via JNK/p38/ERK MAPK and AKT Pathways. Cancers, 15(9), 2468.
https://doi.org/10.3390/cancers15092468
